meta|COVID-19

Dynamic meta-analysis of evidences about drug efficacy and safety

adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
carrimycin
chloroquine and derivatives
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
favipiravir
fluvoxamine
hydroxychloroquine plus macrolides
ivermectin
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
meplazumab
nitazoxanide
oseltamivir
oseltamivir plus chloroquin
remdesivir
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
angiotensin-(1-7)
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
ribavirin
ritonavir
sofosbuvir and daclatasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
triazavirin
umifenovir (arbidol)
control
honey
miscellaneous
vaccines

potential COVID-19 treatments
control
standard of care

All
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission

Studies
Meta-analysis
Excluded

Study		Exclusion reasons	Remarks	Reference(s)
Mehra, 2020	retrospective cohort (claims database)	other	paper retracted	NEJM June 4, 2020 10.1056/NEJMc2021225 Mehra MR et al. NEJM 10.1056/NEJMoa2007621

- About us - Contact us - Method Made with in Lyon - Credits - Privacy policy -